Erik van den Berg has over twenty years’ experience in the pharmaceutical and biotechnology industries. He joined AM-Pharma in September 2007 as Chief Business Officer and became the company’s CEO in 2011.Previously, as a Senior Executive at Organon (NL) he was responsible for leading the Company’s global biotechnology business development.Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik is board member at Lava Therapeutics, Step Pharma, Lead Pharma, Heatmatrix Group and the Dutch biotechnology association and has been involved in the execution of over 20 transactions and partnerships, most recently a $600M alliance with Pfizer and raised more than €400M in equity and debt financing for biotechnology companies from seed through IPO. Erik holds an MSc in Chemistry degree from the University of Utrecht (NL) and an MBA from Manchester Business School (UK) both with distinction.